欧林生物卷入1920万元合同诉讼 涉案账户遭冻结

Core Viewpoint - Oulin Bio (688319) is facing a lawsuit regarding a contract dispute with individual Wang Jianhua, involving a total claim amount of 19.2 million yuan, which includes penalties but excludes litigation costs [1][2]. Group 1: Lawsuit Details - The lawsuit stems from a contract signed in 2011, where the plaintiff claims to have fulfilled obligations by providing two vaccine technologies and is thus entitled to a commission [1]. - Wang Jianhua's claims include a request for 16 million yuan in product commissions, 3.2 million yuan in penalties, and coverage of all litigation costs [1]. Group 2: Company Response - Oulin Bio has acknowledged receipt of legal documents and asserts that the plaintiff's claims lack sufficient factual and legal basis, thus rejecting the claims [2]. - The company emphasizes that the products involved in the lawsuit are legally marketed and compliant with relevant laws and regulations, indicating no significant adverse impact on its operations [2]. Group 3: Financial Impact - The court has frozen one non-basic bank account with a total of 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [2]. - The lawsuit's financial implications remain uncertain until the court reaches a decision, and the company will handle financial reporting in accordance with accounting standards [3]. Group 4: Commitment to Compliance - Oulin Bio, as an innovative technology company, emphasizes its commitment to intellectual property compliance and the regulation of technology cooperation, stating that all R&D activities adhere to legal requirements [3].